Table 1 Patients’ characteristics
From: Patient education needs in severe asthma, a pilot study
Number of patients | 53 |
|---|---|
Age (yrs) (mean ± SD) | 53.5 ± 13.6 |
Age at severe asthma diagnosis (yrs) (mean ± SD) | 49.7 ± 15.1 |
Female gender (n, %) | 30 (56.6) |
Body mass index (kg/m²) (mean ± SD) | 28.9 ± 5.9 |
≥ 30 (n, %) | 18 (33.9) |
Smoking history | |
Current smoker (n, %) | 2 (3.8) |
Ex-smoker (n, %) | 24 (45.3) |
Pack-year (n = 26) (mean ± SD) | 15.7 ± 13.5 |
Comorbidities | |
Nasal polyps (n, %) | 23 (43.4) |
GERD (n, %) | 20 (37.7) |
Allergic rhinitis (n, %) | 12 (22.6) |
Occupation category | |
Manager and intellectual professions (n, %) | 8 (15.1) |
Technical professions (n, %) | 20 (37.7) |
Services (n, %) | 17 (32.1) |
Unemployed (n, %) | 6 (11.3) |
Students (n, %) | 2 (3.8) |
Treatment adherence (MARS score ≥ 21) | 48 (90.6) |
ACT score (mean ± SD) | 17.0 ± 5.3 |
< 15 (n, %) | 16 (30.2) |
15–19 (n, %) | 15 (28.3) |
≥ 20 (n, %) | 22 (41.5) |
Exacerbations | |
In the last year (n, %) | 35 (66) |
Number per patient (median[25th -75th ] | 1 [0–4] |
≥ 2 severe exacerbations in the last year (n,%) | 25 (47.2) |
Blood eosinophils (109/L) * (median[25th -75th ] | 0.60 [0.4–1.0] |
< 150 (n, %) | 2 (3.8) |
150–299 (n, %) | 2 (3.8) |
≥ 300 (n, %) | 49 (92.4) |
Aeroallergen sensitization (n, %) | 26 (49.1) |
FEV1 post bronchodilation, % (mean ± SD) | 80.2 ± 18.6 |
FEV1/FVC (mean ± SD) | 68.2 ± 9.9 |
Treatment at inclusion | |
Inhaled corticosteroid (n, %) | 53 (100) |
Long-acting beta2 agonist (n, %) | 53 (100) |
Long-acting muscarinic antagonist (n, %) | 13 (24.5) |
Montelukast (n, %) | 27 (50.9) |
Long-term oral corticosteroid (previous or current) (n, %) | 16 (30.2) |
OCS dose (mg/day) (mean ± SD) | 12.7 ± 7.7 |
Biologic therapy (current) (n, %) | 49 (92.5) |
1st line (n, %) | 25 (51.0) |
≥2nd line (n, %) | 24 (49.0) |
Previous TPE program (n, %) | 21 (39.6) |
Time from the last TPE program > 1 year (mean ± SD) | 11 (20.8) |